Sulfonylurea (Glipizide/Glyburide) Overdose: Why Blood Sugar Crashes Repeatedly After Glucose¶

Sulfonylureas - including glipizide (Glucotrol, Glucotrol XL), glyburide / glibenclamide (DiaBeta, Glynase, Micronase), glimepiride (Amaryl), gliclazide (Diamicron), and chlorpropamide - as well as rapid-acting meglitinides (repaglinide [Prandin] and nateglinide [Starlix]) are oral Type 2 diabetes medications known as insulin secretagogues. Unlike metformin (which works by improving insulin sensitivity and almost never lowers blood sugar below normal in a healthy person), sulfonylureas bind directly to the Sulfonylurea Receptor-1 (SUR1) subunit of ATP-sensitive potassium (K-ATP) channels on pancreatic beta cells, forcing the pancreas to dump massive, continuous waves of endogenous insulin into the bloodstream regardless of how low the patient's blood sugar drops. Consequently, sulfonylureas are on the pediatric "One Pill Can Kill" list: a single 5 mg or 10 mg tablet of glipizide or glyburide accidentally swallowed by a toddler - or standard daily doses that accumulate in an older adult due to acute kidney injury or a drug interaction (like trimethoprim-sulfamethoxazole [Bactrim] or fluconazole) - causes profound, prolonged, life-threatening neuroglycopenia, seizures, permanent brain damage, and coma lasting 24 to 72+ hours. Worse yet, treating a sulfonylurea overdose like an ordinary insulin reaction by simply pushing repeated boluses of concentrated Intravenous Dextrose (D50W or D25W) alone triggers a vicious rebound hypoglycemia trap: every surge of IV glucose stimulates the sulfonylurea-primed pancreas to release an even bigger spike of insulin, causing blood sugar to crash back down to lethal levels (< 30 mg/dL or < 1.7 mmol/L) 30 to 60 minutes later unless clinicians immediately administer the specific pharmacological antidote, Octreotide (Sandostatin), to shut off pancreatic insulin release at the source.

If a child has swallowed even a single diabetes pill, or if an adult taking glipizide, glyburide, glimepiride, or gliclazide becomes confused, sweaty, shaky, combative, slurred in speech, or unresponsive, call your local emergency number (911 in the United States and Canada, 112 across the European Union, 999 in the United Kingdom) via our emergency numbers directory immediately, and review diabetic emergencies, diabetic ketoacidosis and hyperosmolar state, and seizure first aid.

Do this now¶

1. Call 911 / 112 / 999 and Poison Control immediately and check a fingerstick blood glucose if you have a meter: If the patient is drowsy, confused, slurring words, seizing, or unresponsive, call for an Advanced Life Support (ALS) ambulance immediately. If a toddler or young child may have swallowed even ONE sulfonylurea or meglitinide pill (glipizide, glyburide/glibenclamide, glimepiride, gliclazide, repaglinide), take them to the emergency department immediately - every pediatric sulfonylurea ingestion requires a mandatory 24-hour inpatient hospital admission because severe hypoglycemia can strike suddenly 8 to 18 hours after swallowing the pill (especially while the child is asleep at night).
2. If the person is AWAKE and able to swallow safely, give fast-acting sugar PLUS a complex carbohydrate/protein snack right away: Give 15 to 20 grams of fast-acting glucose (120 mL [4 oz] of regular fruit juice or non-diet soda, 3 to 4 glucose tablets, or 1 tablespoon of honey/sugar dissolved in water), followed immediately by a complex carbohydrate and protein snack (such as peanut butter crackers or a cheese sandwich). Never put food, juice, or gel into the mouth of a drowsy, seizing, or unconscious person.
3. Understand why Glucagon injections (GlucaGen, Baqsimi, Gvoke) often fail or worsen rebound crashes in Sulfonylurea poisoning: If the person is unconscious and no IV is available yet, you may use an emergency intramuscular or intranasal Glucagon kit if one is on hand. However, warn paramedics that glucagon relies on liver glycogen stores (which are rapidly exhausted in sulfonylurea overdose) AND glucagon directly stimulates pancreatic beta cells to secrete MORE insulin, frequently triggering severe rebound hypoglycemia within 30 to 45 minutes.
4. Alert paramedics and emergency room doctors to the "IV Dextrose Rebound Trap" and request OCTREOTIDE: Tell the medical team: "This is a Sulfonylurea (Glipizide / Glyburide / Glimepiride) overdose - repeated D50W boluses alone will trigger rebound insulin spikes; please start Subcutaneous or Intravenous Octreotide right after correcting the low blood sugar."
5. Do NOT restrict food in an asymptomatic child waiting under observation in the hospital: When a child is admitted for 24-hour observation after swallowing a sulfonylurea pill, allow the child to eat a normal diet while checking bedside fingerstick blood sugars every 1 to 2 hours. However, do NOT start a prophylactic intravenous dextrose (D5W or D10W) drip in an asymptomatic child with normal blood sugars, because prophylactic IV glucose hides whether the child actually swallowed the pill until the drip is turned off and the child is sent home into a fatal crash.
6. Check the patient's other medication bottles for "Hidden Sulfonylurea Multipliers": Bring every pill bottle to the hospital. In older adults with Type 2 diabetes, life-threatening sulfonylurea coma is most often triggered not by taking extra pills, but by starting an antibiotic or antifungal (Trimethoprim-Sulfamethoxazole [Bactrim/Septra], Fluconazole [Diflucan], Ciprofloxacin/Levofloxacin, or Clarithromycin) or developing acute kidney injury (AKI), which blocks clearance of active glyburide or glimepiride metabolites.

Decision tree: Managing pediatric and adult sulfonylurea / meglitinide overdose with Octreotide¶

flowchart TD
    Start["Suspected Sulfonylurea (Glipizide, Glyburide/Glibenclamide, Glimepiride, Gliclazide) or Meglitinide (Repaglinide, Nateglinide) Overdose / Accumulation"] --> CheckBG{"Check STAT Bedside Fingerstick & Lab Serum Glucose"}

    CheckBG -->|Hypoglycemic: Blood Glucose < 60-70 mg/dL (< 3.3-3.9 mmol/L) OR Any Neuroglycopenic Symptoms (Confusion, Diaphoresis, Seizures, Coma)| TreatHypo["1. Immediate Glucose Restoration: - Awake/Alert: Oral Glucose (15-20 g) + Complex Carbohydrate Meal - Altered/Unconscious: IV Dextrose Bolus (Adults: D50W 50 mL [25 g]; Children: D25W 2-4 mL/kg OR D10W 5-10 mL/kg [0.5-1 g/kg]) 2. Administer Activated Charcoal (1 g/kg) if < 1-2 Hours Post-Ingestion (Or up to 4-6h for Extended-Release Glipizide XL)"]

    CheckBG -->|Euglycemic & Asymptomatic: Blood Glucose >= 70 mg/dL (>= 3.9 mmol/L)| ObserveProtocol["1. Activated Charcoal (1 g/kg) if < 1-2 Hours Post-Ingestion 2. Allow Normal Oral Diet; DO NOT Start Prophylactic IV Dextrose or Octreotide (Masks Onset) 3. MANDATORY OBSERVATION WITH Q1-2H GLUCOSE CHECKS: - All Pediatric Ingestions & Adult Extended-Release / Glyburide: Admit for Minimum 24 Hours (Includes Overnight Sleep) - Adult Immediate-Release Meglitinide (Repaglinide/Nateglinide): Minimum 8-12 Hours"]

    TreatHypo --> StartOctreotide["IMMEDIATE ANTIDOTE: START OCTREOTIDE (SANDOSTATIN) AFTER FIRST HYPOGLYCEMIC EPISODE (Blocks Beta-Cell Voltage-Gated Calcium Channels to Stop Rebound Insulin Release): - Adults: 50 to 100 mcg Subcutaneous (SC) or IV Every 6 Hours (for at least 24 hours) - Children: 1 to 1.5 mcg/kg (Max 50 mcg) SC or IV Every 6 Hours (Or Continuous IV Infusion at 50-125 ng/kg/min / 25-50 mcg/hr in Refractory Cases)"]

    StartOctreotide --> MaintenanceCare["1. Run Maintenance IV Dextrose (D5W or D10W) Titrated to Keep Blood Glucose 80-120 mg/dL (4.4-6.7 mmol/L) + Unrestricted Oral Diet Once Awake 2. Check Blood Glucose Every 30-60 Minutes Until Stable, Then Every 2 Hours 3. Check Serum Creatinine, Potassium, & Insulin/C-Peptide Levels (Confirm Endogenous Hyperinsulinemia: High Insulin + High C-Peptide)"]

    ObserveProtocol --> DelayedDrop{"Does Blood Glucose Drop < 60-70 mg/dL at Any Point During Observation?"}
    DelayedDrop -->|YES| TreatHypo
    DelayedDrop -->|NO: 100% Euglycemic for 24 Full Hours Without IV Dextrose or Octreotide| SafeDischarge["Safe for Discharge (After Childproofing / Psychiatric or Renal Medication Adjustment)"]

    MaintenanceCare --> WeanProtocol["MANDATORY 24-HOUR POST-OCTREOTIDE OBSERVATION RULE: After Stopping Octreotide & IV Dextrose, Observe Patient in Hospital on Oral Diet Alone for a Full 12 to 24 Additional Hours to Confirm No Late Recurrence (Especially in Renal Failure or Glyburide/Glimepiride)"]

Pathophysiology: How Sulfonylureas Lock the Pancreas "On" and How Octreotide Turns It "Off"¶

1. The Pancreatic Beta-Cell Secretion Cascade (SUR1 -> K-ATP -> VGCC -> Insulin)¶

In a healthy pancreas, beta cells release insulin only when blood glucose rises after a meal:

1. Normal Physiological Glucose Sensing: When blood glucose rises above 80 to 90 mg/dL, glucose enters the pancreatic beta cell via GLUT2 transporters and is metabolized by glycolysis and mitochondria into ATP. The rising intracellular ATP-to-ADP ratio closes ATP-sensitive potassium channels (K-ATP channels) on the cell membrane.
2. Depolarization and Calcium Influx: Because positively charged potassium ions (K+) can no longer leak out of the cell, the beta-cell membrane depolarizes (becomes positively charged). This electrical depolarization opens L-type Voltage-Gated Calcium Channels (VGCC), allowing extracellular calcium (Ca2+) to flood into the beta cell and trigger exocytosis (fusion and release) of pre-formed insulin secretory granules (alongside equimolar C-peptide) into the portal vein.
3. How Sulfonylureas Hijack the Switch: Every K-ATP channel is an octamer built from four pore-forming Kir6.2 subunits surrounded by four regulatory Sulfonylurea Receptor-1 (SUR1) subunits. Sulfonylureas (glipizide, glyburide, glimepiride, gliclazide) and meglitinides (repaglinide, nateglinide) bind directly to the SUR1 subunit and mechanically lock the K-ATP channel shut, completely bypassing the cell's normal ATP glucose sensor. Even when the patient's blood sugar plummets to 15 mg/dL and intracellular ATP drops to starvation levels, the K-ATP channel stays locked shut, calcium keeps pouring in, and the beta cell keeps pumping out lethal amounts of insulin while simultaneously suppressing hepatic gluconeogenesis and glycogenolysis.

2. Why Octreotide Is the Perfect Physiological Antidote (Downstream Calcium Blockade)¶

Because sulfonylureas lock the SUR1 / K-ATP channel at the top of the cascade, giving more glucose (D50W) only increases intracellular ATP and amplifies calcium influx and insulin exocytosis once the sulfonylurea concentration begins to dip or plateau.

• How Octreotide Works: Octreotide is a long-acting synthetic octapeptide analog of the hormone somatostatin. When injected subcutaneously or intravenously, Octreotide binds to Somatostatin Subtype-2 and Subtype-5 (SSTR2 and SSTR5) G-protein-coupled receptors on the pancreatic beta-cell membrane.
• Direct Downstream Interruption: Activation of SSTR2 / SSTR5 directly inhibits the voltage-gated calcium channels (VGCC) and inhibits adenylate cyclase (cAMP) and distal insulin granule exocytosis. Because the voltage-gated calcium channels sit downstream of the SUR1 / K-ATP channel, Octreotide shuts off calcium entry and completely halts insulin secretion even while the sulfonylurea is still tightly bound to the SUR1 receptor.
• Alternative Second-Line Antidote (Diazoxide): Before Octreotide became standard of care, clinicians used Diazoxide (Proglycem), a non-diuretic benzothiadiazine that directly opens K-ATP channels. Today, Octreotide is strongly preferred over Diazoxide because Diazoxide causes severe reflex tachycardia, systemic hypotension, fluid retention, and vomiting, whereas Octreotide is hemodynamically safe, easy to give subcutaneously (50 to 100 mcg SC Q6H), and vastly more effective at eliminating recurrent hypoglycemic crashes.

Master Comparison Table: Oral Diabetes Drugs in Overdose (Which Ones Cause Lethal Hypoglycemia?)¶

Because patients with Type 2 diabetes frequently take multiple oral medications, identifying which exact drug class was ingested determines whether the patient is at risk for lethal hypoglycemia:

Step-by-Step Hospital and EMS Dosing Protocol: Dextrose, Octreotide, and Decontamination¶

1. Weight-Based Intravenous Dextrose Correction (Avoiding Extravasation Necrosis and Rebound Spikes)¶

When a patient presents with sulfonylurea-induced hypoglycemia (blood glucose < 60 mg/dL [3.3 mmol/L] or any neuroglycopenic symptoms), restore normal brain glucose immediately using the lowest effective concentration of intravenous dextrose to minimize vein irritation and limit excessive pancreatic beta-cell stimulation:

• Adults: Administer 25 to 50 mL of 50% Dextrose (D50W, containing 12.5 to 25 grams of glucose) via a secure peripheral or central IV line (or 100 to 250 mL of 10% Dextrose [D10W] infused rapidly over 5 to 10 minutes, which causes less phlebitis and a smoother glycemic curve than D50W).
• Children and Toddlers: Never push D50W into a small child's peripheral vein (its extreme hyperosmolarity [2,525 mOsm/L] causes severe vein sclerosis and full-thickness tissue necrosis if it extravasates). Instead, follow the pediatric "Rule of 50" (Dose in mL/kg x % Dextrose = 50, which delivers 0.5 grams/kg of glucose):
• 10% Dextrose (D10W, preferred in infants and young children): Administer 5 mL/kg (0.5 g/kg) IV bolus (up to 10 mL/kg [1 g/kg] for severe hypoglycemic seizures).
• 25% Dextrose (D25W, older children): Administer 2 mL/kg (0.5 g/kg) to 4 mL/kg (1 g/kg) IV bolus.
• Thiamine Co-Administration in Malnourished or Alcoholic Adults: In adults with chronic alcohol use disorder or severe malnutrition, administer 100 mg of Intravenous Thiamine (Vitamin B1) alongside (never delaying) the initial dextrose bolus to prevent acute Wernicke encephalopathy.

2. Exact Octreotide (Sandostatin) Regimen and Continuous Infusion Titration¶

Immediately after correcting the very first hypoglycemic episode (or immediately upon arrival if pre-hospital EMS already administered IV dextrose or oral sugar for a documented low blood glucose), start Octreotide:

1. Intermittent Subcutaneous (SC) or Intravenous (IV) Dosing (Standard First-Line Protocol):
2. Adults: 50 mcg to 100 mcg subcutaneously (SC) or slowly intravenously (IV) every 6 hours for at least 24 hours. (Clinical tip: Subcutaneous injection provides a smooth, sustained depot effect over 6 to 8 hours and avoids the brief nausea or bradycardia occasionally seen with rapid IV pushes).
3. Pediatric Patients: 1 to 1.5 mcg/kg (up to a maximum of 50 mcg per dose) subcutaneously (SC) or IV every 6 hours for at least 24 hours.
4. Continuous Intravenous Octreotide Infusion (For Massive Intentional Overdoses or Refractory Hypoglycemia):
5. If a patient swallowed dozens of extended-release Glucotrol XL or Glyburide tablets and continues to experience blood glucose drops between intermittent Q6H doses, administer an initial 50 to 100 mcg IV bolus (1 to 1.5 mcg/kg in children) followed immediately by a continuous IV Octreotide infusion at 25 mcg/hour to 50 mcg/hour in adults (or 50 to 125 ng/kg/minute [3 to 7.5 mcg/kg/hour] in children).
6. Gastrointestinal Decontamination for Immediate-Release vs. Extended-Release (Glucotrol XL) Tablets:
7. Single-Dose Activated Charcoal (1 g/kg, max 50 g): Administer orally if the patient presents within 1 to 2 hours of ingestion and is fully awake and protecting their airway.
8. Extended-Release Glipizide (Glucotrol XL) "GITS" Osmotic Pump Shells: Glucotrol XL uses a non-absorbable laser-drilled cellulose-acetate membrane (Gastrointestinal Therapeutic System, GITS) that slowly pumps glipizide out over 16 to 24 hours as it transits the entire bowel. In large intentional overdoses of Glucotrol XL, administer Activated Charcoal up to 4 to 6 hours post-ingestion and consider Whole-Bowel Irrigation (WBI) with Polyethylene Glycol Electrolyte Solution (PEG-ES at 1.5 to 2 L/hr in adults or 25 mL/kg/hr in children) to flush unabsorbed osmotic pump shells out of the gastrointestinal tract.

3. The 6 Major Drug-Drug and Renal Triggers That Precipitate Sulfonylurea Coma in Older Adults¶

Over 70 percent of hospital admissions for severe sulfonylurea hypoglycemia in adults over age 65 occur in patients taking their regular prescribed dose who encounter one of six precipitating triggers:

1. CYP2C9 Enzyme Inhibitors (Bactrim, Fluconazole, Metronidazole, Amiodarone): Hepatic cytochrome P450 CYP2C9 is the primary enzyme that metabolizes glipizide, glyburide, glimepiride, and tolbutamide. Starting a 5-day course of trimethoprim-sulfamethoxazole (Bactrim / Septra) for a urinary tract infection or fluconazole (Diflucan) for a yeast infection increases sulfonylurea blood concentrations by 200% to 400% within 48 hours.
2. Fluoroquinolone Antibiotics (Ciprofloxacin, Levofloxacin, Moxifloxacin): Directly block pancreatic beta-cell K-ATP channels alongside sulfonylureas AND inhibit CYP enzymes, causing sudden, notoriously severe dysglycemia and hypoglycemic coma (carrying an FDA Boxed Warning).
3. Gemfibrozil + Repaglinide (CYP2C8 + OATP1B1 Blockade): Taking the cholesterol fibrate drug gemfibrozil (Lopid) with the meglitinide repaglinide (Prandin) increases repaglinide blood levels 8.1-fold (810%) and prolongs its half-life from 1 hour to over 12 hours; if itraconazole is also present, levels rise 19-fold.
4. Non-Selective Beta-Blockers (Propranolol, Nadolol, Carvedilol): Mask the sympathetic adrenergic early warning signs of falling blood sugar (blocking tremors, palpitations, and anxiety, while leaving cholinergic sweating [diaphoresis] intact) and simultaneously block beta-2-mediated hepatic glycogenolysis, so the patient goes straight from feeling normal into sudden neuroglycopenic coma without warning.
5. Salicylate (Aspirin) Overdose or High-Dose NSAIDs: Displace sulfonylureas from plasma albumin binding sites and directly stimulate insulin secretion while inhibiting gluconeogenesis.
6. Acute Kidney Injury (AKI) or Progressive Chronic Kidney Disease (CKD): While glipizide is metabolized in the liver to inactive products, glyburide (glibenclamide) and glimepiride are converted into active hydroxylated metabolites (4-trans-hydroxyglyburide and M1) that depend entirely on the kidneys for excretion. If an older adult on glyburide develops mild dehydration from viral gastroenteritis or starts an ACE inhibitor/NSAID, those active metabolites accumulate for 3 to 5 days, causing relentless hypoglycemia.

Forensic Lab Clue: Differentiating Sulfonylurea Overdose from Exogenous Insulin Injection (Insulin vs. C-Peptide)¶

When an adult or child presents with unexplained, refractory hypoglycemia (blood glucose < 40 mg/dL) and no clear history of pill ingestion, drawing a single extra red-top/green-top blood tube during the hypoglycemic episode (before or right as IV Dextrose is given) for Serum Insulin, C-Peptide, Beta-Hydroxybutyrate, and a Sulfonylurea Toxicology Screen immediately solves the diagnosis:

• Endogenous Pancreatic Hyperinsulinemia (Sulfonylurea / Meglitinide Overdose OR Insulinoma): Because the patient's own pancreatic beta cells manufacture proinsulin, which splits 1:1 into 1 molecule of Insulin + 1 molecule of C-Peptide, BOTH Serum Insulin AND Serum C-Peptide are markedly ELEVATED (Insulin > 3 mcIU/mL and C-Peptide > 0.6 ng/mL during hypoglycemia), and a plasma/urine Sulfonylurea Screen is positive.
• Exogenous Pharmaceutical Insulin Injection (Factitious / Malicious / Accidental Insulin Overdose): Commercial injectable insulins (Humulin, Novolog, Lantus, Humalog) are purified without C-peptide, and the injected insulin suppresses the patient's own pancreas. Therefore, Serum Insulin is SKY-HIGH while Serum C-Peptide is SUPPRESSED / UNDETECTABLE (< 0.2 ng/mL).

Regional emergency numbers and agency protocols¶

Frequently asked questions¶

Why does giving an intravenous Dextrose (D50W) sugar shot by itself cause the patient's blood sugar to crash even harder 30 minutes later?¶

In a sulfonylurea overdose, the drug is tightly bound to the pancreatic beta cells, holding their potassium channels closed so the pancreas is primed to release insulin continuously. When a doctor or paramedic pushes a concentrated 50% Dextrose (D50W) bolus into a vein without giving Octreotide, the sudden spike in blood sugar floods into the pancreatic beta cells and triggers a massive, explosive surge of brand-new insulin secretion. Within 30 to 60 minutes, that huge rebound wave of insulin wipes out all the injected glucose and drives the patient's blood sugar right back down to life-threatening levels.

How does Octreotide stop low blood sugar in a Glipizide or Glyburide overdose?¶

Octreotide is a synthetic version of the natural hormone somatostatin. While sulfonylureas like glipizide and glyburide force the pancreatic beta cell's potassium channels shut at the start of the electrical pathway, the beta cell still cannot release insulin unless calcium ions flow in through voltage-gated calcium channels at the end of the pathway. Octreotide binds to somatostatin receptors on the beta cell and directly shuts those downstream voltage-gated calcium channels - turning off pancreatic insulin secretion within minutes even while the sulfonylurea pill is still in the body.

Why can't a doctor start a preventative intravenous sugar drip (D5W or D10W) right away on a toddler who may have swallowed a Glipizide pill but still has a normal blood sugar?¶

When a young child is brought to the emergency room after finding an open bottle of glipizide or glyburide, doctors often do not know for sure whether the child actually swallowed a pill or just dropped it on the floor. If a doctor hooks the asymptomatic child up to a preventative IV dextrose drip or gives Octreotide right away while blood sugar is normal, the drip will artificially mask the drop in blood sugar for several hours, leading the team to falsely conclude no pill was swallowed and discharge the child home just as the pill peaks - or requiring days of unnecessary hospitalization. Instead, asymptomatic children are admitted for 24 hours on a normal diet without IV glucose while checking fingerstick blood sugars every 1 to 2 hours, starting IV Dextrose and Octreotide the instant a true drop below 60 to 70 mg/dL occurs.

Why do older adults who have taken the same dose of Glyburide or Glimepiride safely for years suddenly fall into a hypoglycemic coma after starting the antibiotic Bactrim (Trimethoprim-Sulfamethoxazole) or Fluconazole?¶

Sulfonylureas like glipizide, glyburide, and glimepiride are broken down in the liver by the cytochrome P450 enzyme CYP2C9 and excreted by renal tubular transporters. Common antibiotics and antifungals - especially Sulfamethoxazole-Trimethoprim (Bactrim/Septra), Fluconazole (Diflucan), Metronidazole, and Fluoroquinolones (ciprofloxacin, levofloxacin) - potently inhibit the CYP2C9 enzyme and block renal clearance, causing the patient's normal daily diabetes pill to build up in the blood to 3 to 5 times its normal concentration and triggering severe, prolonged hypoglycemic coma.

Why does a patient have to stay in the hospital for another 12 to 24 hours AFTER their Octreotide injections and IV sugar drips are stopped?¶

Octreotide has a half-life of only a few hours, whereas sulfonylureas in overdose (especially extended-release Glipizide XL, long-acting Chlorpropamide, or active metabolites of Glyburide and Glimepiride in patients with reduced kidney function) can remain bound to the pancreas for 36 to 72+ hours. While the patient is receiving Octreotide every 6 hours, their blood sugar will look completely normal because Octreotide is holding the pancreas shut. The only way to prove that the sulfonylurea has finally cleared the body is to stop the Octreotide and IV dextrose and monitor the patient on regular meals alone for 12 to 24 full hours to verify that hypoglycemia does not rebound.

Related guides¶

• Diabetic emergencies: hypoglycemia and hyperglycemia first aid
• Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS)
• Status epilepticus, prolonged seizures, and rescue medications
• Acute kidney injury, rhabdomyolysis, and dark urine triage
• Poisoning first aid and poison control triage

Sources and official guidance¶

• American College of Medical Toxicology (ACMT) & America's Poison Centers: Evidence-Based Consensus Guideline for Out-of-Hospital Management of Sulfonylurea Ingestions and Antidote Stocking Guidelines for Octreotide.
• American Diabetes Association (ADA) & Endocrine Society: Standards of Care in Diabetes: Evaluation and Management of Adult and Pediatric Hypoglycemic Disorders and Sulfonylurea Toxicity.
• Royal College of Emergency Medicine (RCEM) & National Poisons Information Service (NPIS, United Kingdom): TOXBASE Clinical Protocol for Sulfonylurea Overdose and Category A Antidote Stocking of Octreotide.
• Extracorporeal Treatments in Poisoning (EXTRIP) & Clinical Toxicology Collaborative: Pediatric "One Pill Can Kill" Guidance: Mandatory 24-Hour Observation and Octreotide Rescue in Sulfonylurea Exposures.
• World Health Organization (WHO): Model Formulary and Management of Severe Hypoglycemia from Oral Insulin Secretagogues (Glibenclamide / Gliclazide).

This guide is for informational purposes and does not replace professional emergency medical evaluation, Poison Control consultation, or inpatient hospital monitoring. Because a single sulfonylurea tablet can cause delayed, recurrent hypoglycemic seizures and coma, we strongly recommend taking an accredited hands-on first aid and CPR course through the International Federation of Red Cross and Red Crescent Societies (IFRC), your national Red Cross society, St John Ambulance, or a certified local provider.